X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, the company will utilize OT-101 (trabedersen), currently under investigation in mid-stage clinical trials with adult patients, for treating brain cancer and diffuse intrinsic pontine glioma.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mosaic ImmunoEngineering
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2024
Details:
OT-101, is a first-in-class anti-TGF-β2 RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer (metastatic pancreatic cancer) patients. TGF-β2 has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG.
Lead Product(s): Trabedersen,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cromos Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
OT-101 - a TGF-β antisense- is active against recurrent glioblastoma in G004- a phase 2 clinical trial. OT-101 was delivered intratumorally by Convection Enhanced Delivery (CED).
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 12, 2022
Details:
Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or superior to Remdesivir.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mateon Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
OT-101 (trabedersen) an antisense against TGF-β2 – for the treatment of solid tumors with focus on brain cancer in adult and DIPG in children. RPD for pediatric DIPG granted by US FDA.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
More than half of OT-101 (trabedersen) treated PC patients went into long term disease control (21 of 37 pts, 55%) allowing them to enter into subsequent chemotherapy which has an unexpected benefit of more than doubling their median OS, 9.3 vs. 2.6 mos, p<0.0001.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sapu Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
OT-101 (trabedersen), an antisense against TGF-β2 –for the treatment of various viruses, including the SARS and the current COVID-19, on its own and in conjunction with other compounds.
Lead Product(s): Trabedersen,Pembrolizumab
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Initial focus on the further development and commercialization of OT-101, including for DIPG as wellas pancreatic cancers and glioblastoma. OT-101 has completed seven clinical trials including phase 2 trial in COVID and two phase 2 trials in brain cancer and pancreatic cancer.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dragon Overseas
Deal Size: $77.6 million Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2022
Details:
OT-101 is a first-in-class anti-TGF-? ribonucleic acid therapeutic exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials has a significant potential to help both cancer and COVID patients in the future.
Lead Product(s): Trabedersen,Pembrolizumab
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
Company submitted clinical study protocol to the US FDA for the initiation of a Phase 2 Trial for OT-101 (Trabedersen), a TGF-β inhibitor used in combination with Anti-PD-1 (Keytruda®) as a treatment for Malignant Pleural Mesothelioma.
Lead Product(s): Trabedersen,Pembrolizumab
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
Golden Mountain Partners, and Oncotelic pharmaceutical are forming a joint venture to advance clinical development of Oncotelic's lead product OT-101 and build out of manufacturing facilities for the commercial launch of Oncotelic's drug candidates.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Golden Mountain Partners
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Agreement August 16, 2021
Details:
Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oncotelic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe disease requiring mechanical ventilation or intubation.
Lead Product(s): Trabedersen,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mateon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 24, 2020
Details:
GMP and Mateon are working to ensure safety and efficacy of OT-101 and Artemisinin for COVID-19 patients. OT-101 is an antisense against host TGF-β protein required for viral replication.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
OT-101 has demonstrated robust efficacy against pancreatic cancer, glioblastoma, and melanoma during phase 2 clinical trials. The demonstration that OT-101 will synergize with IL-2 further demonstrate its utility as adjunct to other immunotherapies.
Lead Product(s): Trabedersen,Aldesleukin
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Autotelic BIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 10, 2020
Details:
The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in the US.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
OT101 administered intratumorally via the CEDOT platform exhibited clinically meaningful single-agent activity and induced durable complete response, partial response in more than half patients.
Lead Product(s): Trabedersen,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
Mateon intends to leverage on the AI machine vision technology used in the retail use cases to pharmaceutical manufacturing, especially with lead product OT-101, for COVID-19.
Lead Product(s): Trabedersen
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mateon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
